JP2020183389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020183389A5 JP2020183389A5 JP2020108569A JP2020108569A JP2020183389A5 JP 2020183389 A5 JP2020183389 A5 JP 2020183389A5 JP 2020108569 A JP2020108569 A JP 2020108569A JP 2020108569 A JP2020108569 A JP 2020108569A JP 2020183389 A5 JP2020183389 A5 JP 2020183389A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- gdf11
- receptor type
- activin receptor
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718126P | 2012-10-24 | 2012-10-24 | |
| US61/718,126 | 2012-10-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131226A Division JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020183389A JP2020183389A (ja) | 2020-11-12 |
| JP2020183389A5 true JP2020183389A5 (enExample) | 2021-02-25 |
| JP7146850B2 JP7146850B2 (ja) | 2022-10-04 |
Family
ID=50545462
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
| JP2018131226A Pending JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
| JP2020108569A Active JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
| JP2018131226A Pending JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150276766A1 (enExample) |
| EP (2) | EP2912462B1 (enExample) |
| JP (3) | JP6401171B2 (enExample) |
| CN (2) | CN104968801B (enExample) |
| AU (3) | AU2013334659B2 (enExample) |
| CA (1) | CA2889209C (enExample) |
| ES (2) | ES3031001T3 (enExample) |
| IL (3) | IL290653B2 (enExample) |
| SA (1) | SA515360337B1 (enExample) |
| WO (1) | WO2014066486A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EP2781222B1 (en) | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| JP2010539236A (ja) | 2007-09-18 | 2010-12-16 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| EP3290439B1 (en) | 2009-06-12 | 2020-09-02 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| BR112016024319B1 (pt) * | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP3224361B1 (en) * | 2014-11-24 | 2019-06-19 | Somalogic, Inc. | Nucleic acid compounds for binding growth differentiation factor 11 |
| TWI730949B (zh) * | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| SI3286206T1 (sl) | 2015-04-22 | 2021-07-30 | Biogen Ma Inc. | Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase |
| JP6976859B2 (ja) * | 2015-05-13 | 2021-12-08 | セルジーン コーポレイション | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| EP3298034A4 (en) * | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CN105738614B (zh) * | 2016-02-23 | 2017-12-05 | 山东大学 | 一种应用流式细胞仪分析评价小鼠骨髓红细胞生成功能的方法 |
| HUE067225T2 (hu) | 2016-07-27 | 2024-10-28 | Acceleron Pharma Inc | Mielofibrózis kezelésére szolgáló készítmények |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| AU2021273065A1 (en) | 2020-05-15 | 2022-12-15 | Celgene Corporation | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| WO1996001845A1 (en) * | 1994-07-08 | 1996-01-25 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| JP2001513982A (ja) | 1997-08-29 | 2001-09-11 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | フォリスタチン−３ |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| JP4429728B2 (ja) * | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
| US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| EP1824796A4 (en) | 2004-11-16 | 2010-02-17 | Avidia Res Inst | PROTEIN SKELETONS AND USES THEREOF |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| WO2008076437A2 (en) * | 2006-12-18 | 2008-06-26 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TW201803890A (zh) * | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| CN102131822A (zh) * | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| CA2993053A1 (en) * | 2009-04-27 | 2010-11-04 | Novartis Ag | Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth |
| CN102655872B (zh) * | 2009-08-13 | 2016-01-20 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| KR20130132824A (ko) * | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
-
2013
- 2013-10-23 EP EP13848471.2A patent/EP2912462B1/en active Active
- 2013-10-23 IL IL290653A patent/IL290653B2/en unknown
- 2013-10-23 ES ES19184182T patent/ES3031001T3/es active Active
- 2013-10-23 JP JP2015539750A patent/JP6401171B2/ja active Active
- 2013-10-23 US US14/438,120 patent/US20150276766A1/en not_active Abandoned
- 2013-10-23 IL IL267663A patent/IL267663B/en unknown
- 2013-10-23 CN CN201380067792.8A patent/CN104968801B/zh active Active
- 2013-10-23 EP EP19184182.4A patent/EP3608419B1/en active Active
- 2013-10-23 CA CA2889209A patent/CA2889209C/en active Active
- 2013-10-23 ES ES13848471T patent/ES2753811T3/es active Active
- 2013-10-23 CN CN202110622231.6A patent/CN113604550A/zh active Pending
- 2013-10-23 WO PCT/US2013/066350 patent/WO2014066486A2/en not_active Ceased
- 2013-10-23 AU AU2013334659A patent/AU2013334659B2/en active Active
-
2015
- 2015-04-21 IL IL238414A patent/IL238414B/en active IP Right Grant
- 2015-04-23 SA SA515360337A patent/SA515360337B1/ar unknown
-
2018
- 2018-03-09 US US15/916,634 patent/US20190049469A1/en not_active Abandoned
- 2018-07-11 JP JP2018131226A patent/JP2018184428A/ja active Pending
-
2019
- 2019-06-12 AU AU2019204098A patent/AU2019204098B2/en active Active
-
2020
- 2020-06-24 JP JP2020108569A patent/JP7146850B2/ja active Active
-
2021
- 2021-09-21 AU AU2021236465A patent/AU2021236465B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016500698A5 (enExample) | ||
| Fishbane et al. | Brenner & Rector's the kidney | |
| Hashizume et al. | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production | |
| JP2018184428A5 (enExample) | ||
| BR112021010789A2 (pt) | Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar | |
| HU206988B (en) | Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient | |
| KR20210046716A (ko) | 표적화된 TGF-β 억제에 의한 삼중 음성 유방암의 치료 | |
| JP2017031209A (ja) | アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法 | |
| Bruggers et al. | Acquired von Willebrand disease in twins with autoimmune hypothyroidism: response to desmopressin and L-thyroxine therapy | |
| CN109476733A (zh) | 使用il-17拮抗剂治疗新发斑块型银屑病的方法 | |
| KR20230086674A (ko) | 파킨슨 질환의 치료 | |
| Baez-Villasenor et al. | The blood picture in Addison’s disease | |
| CN116782934A (zh) | 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途 | |
| WO2023211864A1 (en) | Use of lat1 inhibitors to treat obesity | |
| CN120112294A (zh) | 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法 | |
| WO2022235636A1 (en) | Combination therapy of carboplatin and napi2b-targeted polymer antibody-drug conjugate for the treatment of ovarian cancer | |
| US20260098087A1 (en) | Dosages of emactuzumab | |
| WO2004043340A2 (en) | Alpha 5 beta 1 and its ability to regulate the cell survival pathway | |
| JP2016106121A (ja) | Ｔｈ３マーチ関連疾患の治療及び予防用医薬組成物 | |
| Schmid et al. | New strategies for managing anemia of chronic kidney disease | |
| JP7737395B2 (ja) | サイトカインストーム症候群の治療のためのペプチド | |
| Richie et al. | Sickle cell trait: forgotten cause of hematuria in white patients | |
| JP2016169205A (ja) | 汗分泌促進剤及び該汗分泌促進剤を含有するドライスキンの予防薬又は治療薬 | |
| Sun et al. | Insulin-like growth factor-1 inhibits colonic smooth muscle cell apoptosis in diabetic rats with colonic dysmotility | |
| RU2834279C1 (ru) | Пептид для лечения синдрома цитокинового шторма |